Skip to main content
AVBP
NASDAQ Life Sciences

ArriVent BioPharma Expands ATM Program to Authorize Up To $250M in Stock Sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$29.02
Mkt Cap
$1.346B
52W Low
$16.1
52W High
$32.14
52W Position info
80% above low
Off High info
9.7% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

AVBP sits 80% above its 52-week low of $16.1.

Summary

ArriVent BioPharma updated its existing ATM program, authorizing the sale of up to $250 million in common stock, providing capital flexibility but also significant potential dilution.


Key Events · Financing and Capital Events · AVBP

  • Expanded At-The-Market (ATM) Program

    The company filed a prospectus supplement to its existing ATM program, authorizing the sale of up to $250,000,000 of common stock from time to time.

  • Potential for Significant Dilution

    If all authorized shares were issued, dilution would be approximately 18.6% of the current market capitalization, representing a substantial potential for dilution for existing shareholders.

  • Capital Raising Flexibility

    This expansion provides ArriVent BioPharma with significant flexibility to raise capital as needed, supporting its operations and pipeline development.

  • Update to Existing Program

    This is an update to an existing ATM program established on February 3, 2025, not a new launch.


Analysis · AVBP · Life Sciences

ArriVent BioPharma has significantly increased the authorized amount for its existing At-The-Market (ATM) equity offering program to $250 million. This provides the company with substantial flexibility to raise capital, which is crucial for a life sciences company. However, if fully utilized, this program represents a considerable potential for dilution for current shareholders, creating an overhang on the stock. This update follows a 10-Q filed on the same day, which highlighted the company's strong liquidity and ongoing ATM sales.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVBP was trading at $29.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $16.10 to $32.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVBP - Latest Insights

AVBP
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.52 info
Change: -$3.64 (-26%) info
Market Cap: $544.127M info
AVBP
Nov 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.52 info
Change: -$3.64 (-26%) info
Market Cap: $544.127M info
AVBP
Nov 09, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.52 info
Change: -$3.64 (-26%) info
Market Cap: $544.127M info
AVBP
Oct 26, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.30
Real-time Price: $10.52 info
Change: -$12.78 (-55%) info
Market Cap: $544.127M info
AVBP
Oct 12, 2026, 5:29 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.46
Real-time Price: $10.52 info
Change: -$5.94 (-36%) info
Market Cap: $544.127M info